Xenetic Bio Share Discussion Threads

[steffyloveshares] 31/1/2014 11:09

video interview
Xenetic Bioscience chief "extremely excited" about the Baxter deal

Xenetic Bioscience (OTCBB:GAIFD) chief executive Scott Maguire said he is "extremely excited" about the tie-up with healthcare giant Baxter, which has a headline value of US110mln, and its commitment to company. A total of US$10mln is being invested directly into Xenetic, which will make Baxter its second-largest shareholder.

[looby loo] 30/1/2014 22:18

30 January 2014
Xenetic Bio in landmark tie-up with Baxter

www.proactiveinvestors.co.uk/companies/news/65356/xenetic-bio-in-landmark-tie-up-with-baxter-65356.html

[looby loo] 30/1/2014 21:56

Proactive Investors interview with Scott Maguire
30 January 2014

Xenetic Bioscience chief "extremely excited" about the Baxter deal:

[holly_dog] 30/1/2014 16:22

We're still stifled by the lack of liquidity until the 130m odd shares become active unfortunately. But highly encouraging. Let's hope more to come in the coming days, we still have other potential areas of newsflow
- Onco
- Corporate appointments
- ErepoXen
- Big pharma..

[ashthorpedo] 30/1/2014 16:17

This is brilliant news buying shares at 93.5c each. Equivalent to approx 18p per old shares. (93.5c/1.65/3.125)

[heyho2] 30/1/2014 13:31

Wow that's brilliant news!I wonder if it was conditional on a move to the US?Be great to see what price the shares open up at following this!

[holly_dog] 30/1/2014 12:12

Excellent news! This hopefully removes the need for a cash raising upon listing, and may keep us going until we list on main market (NASDAQ). Great vote of confidence from Baxter

Xenetic Biosciences Announces Restructured Licensing Agreement With Baxter Now Totaling Up to $100 Million, in Addition to $10 Million Equity Investment
GlobeNewswire, Thursday, 30 January 2014, 12:01 GMT, 796 Words, © Copyright 2014 GlobeNewswire, Inc. All Rights Reserved.
(Document PZON000020140130ea1u0000t)

Xenetic Biosciences Announces Restructured Licensing Agreement With Baxter Now Totaling Up to $100 Million, in Addition to $10 Million Equity Investment

LEXINGTON, Mass., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:GAIFD), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced that it has received a direct investment of $10 million from Baxter International, Inc. and has agreed to a restructuring of certain financial and timing aspects of its existing licensing deal with Baxter. The amended license agreement includes increased contingent milestone payments, now totaling up to $100 million, as well as increased royalties on sales.

"We are extremely pleased by Baxter's commitment to Xenetic and to our longstanding collaboration to develop polysialylated blood coagulation factors using Xenetic's unique technology," said Scott Maguire, Chief Executive Officer of Xenetic. "The new terms in our agreement represent enhanced economics for Xenetic. Additionally, we expect to utilize the capital resulting from Baxter's equity investment to further advance our development pipeline programs, particularly in the orphan drug arena, which feature a number of potential near-term, value-creating clinical milestones. This important new investment from our leading license partner is a genuinely dynamic development for the Company as we start our new life in the United States and it augurs well for our future in the world's leading economy and pharmaceutical market."

Brian Goff, head of Baxter's hemophilia organization, commented, "Through our Xenetic partnership, we are seeking to identify and develop a treatment that the majority of hemophilia patients could administer less frequently, potentially at once weekly intervals, without compromising efficacy. Our investment in Xenetic reflects our continued commitment to the hemophilia community and to our pursuit of a bleed-free world."

In August 2005, Xenetic and Baxter established an exclusive worldwide agreement to develop novel forms of polysialylated blood coagulation factors, including Factor VIII, using Xenetic technology to conjugate polysialic acid (PSA) to therapeutic blood-clotting factors. The goal of the program is to improve the pharmacokinetic profile and extend the active life of these factors, thereby improving upon existing therapies and increasing quality of life of patients.

[holly_dog] 30/1/2014 08:13

This is the link with the filing date

hxxp://www.sec.gov/Archives/edgar/data/1534525/000150416714000058/0001504167-14-000058-index.htm

[holly_dog] 30/1/2014 08:11

Looks as though the last of the paperwork has now gone through the SEC as of 16.50 US time yesterday. I guess that the new 130m shares will be allocated and can be traded dependent on individual brokers.

hxxp://www.sec.gov/Archives/edgar/data/1534525/000150416714000058/mainbody.htm

Hopefully we'll get some sort of an RNS today?

[buywell2] 29/1/2014 22:12

Engage brain c before keyboard

[earnestwipplethwaiteiii] 29/1/2014 13:07

corrientes - hxxp://www.otcmarkets.com/stock/GAIFD/quote

This will of course consolidate when the new shares enter next week.

[corrientes] 29/1/2014 12:30

On another board, some 'knowledgable' (?) posters, are I think, quoting actual prices in dollars already for Xenetic Inc, but I make it only a few cents according to the ticker I'm using. I must be right, unfortunately. LOL.

[ashthorpedo] 29/1/2014 11:55

hxxp://www.ddfevent.com/2014-speakers/

He is speaking at the World Drug Delivery & Formulation 2014 summit as well on 17th - 19th February 2014 so maybe we might get some news before this.

[holly_dog] 28/1/2014 12:46

Very nice find. How did you unearth that!

One would suspect it would be strange to line up a slot at the conference to present PIII results if they were not likely to be positive.

So in the meantime we wait until the shares get lodged. Speaking with my broker today they will go in on the 7th Feb.

[heyho2] 28/1/2014 11:22

Whilst we're waiting for news of our US listing its interesting to note that Xenetic will be presenting on progress with ErepoXen in May:http://www.cipf.es/documents/10157/56e82f7b-7cd3-41d8-8cf9-4c2791764c17"Sanjay Jain (Xenetic Biosciences plc) - Phase II clinical studies with ErepoXen® (polysialyated insulin)and Phase III clinical update"

[heyho2] 22/1/2014 16:20

Well here we go; last day of trading on AIM. MMs doing their housekeeping and dumping unwanted stock.Goodbye AIM, and quickly frankly, good riddance!Hello US and here's to a better rating of the companies value!Good Luck All Investors

[holly_dog] 21/1/2014 12:16

Is there going to be some massive balancing trades later today/tomorrow as the MMs unwind their books?

They must have restrictions on trying to play the arbitrage game and holding to the US?

[earnestwipplethwaiteiii] 21/1/2014 12:07

Ash - yes, as always; no charity on AIM.

[ashthorpedo] 21/1/2014 11:45

The MM's are having a field day. They know that anyone selling is a forced seller and are giving them bottom dollar.

[holly_dog] 20/1/2014 18:19

Yes and no. I agree, the real fireworks will be on the 27th (hopefully!). However it would be interesting if there was a last minute surge to further support the arbitrage argument.

[heyho2] 20/1/2014 17:52

HollyThe price we exit AIM with is irrelevant, it's the opening price of the US listing that will be telling!

[holly_dog] 20/1/2014 17:45

Two trading days left. Will be interesting to see if we get any last minute fireworks

[holly_dog] 20/1/2014 11:18

On a positive note - if your broker is dumping today there is clearly a buyer hoovering it up given the price is holding

[kloos2] 20/1/2014 11:14

Sure it is water under the bridge earnestwipplethwaiteIII. I would assume that mine is a part of that sale as the broker was selling for all of their clients. Anyhoo. Onwards and upwards. Good luck to the rest of you when it switches to the other side of the pond.